Your desk is ready
Free to start · no card required · your pick is waiting on the other side.
Niche's weekly rollup — one email, no spam.
The stories refresh every few hours from live news and primary sources. Each carries the publisher and the date it was published — so you can see exactly how current it is.
Real reporting and primary filings — every story links its sources. Nothing here is a generated guess; the angle is identified and the receipts are attached.
Yes. These are starting points for your own posts. Draft one and Niche writes it in your voice, platform-native, ready to publish.
Right now, the biggest stories for biotech & pharma professionals: Biotechs lean hard on FDA alignment after a turbulent year; Oncology readouts keep the ADC and bispecific race hot; Big pharma is buying faster as pipelines and patents tighten — and 2 more. Real stories, real sources, updated every few hours. Not generated guesses.
todayMultiple biotech updates center on companies emphasizing alignment with the FDA on trial design, approval pathways, and label expansion after a year of regulatory whiplash. This includes positive pre-IND feedback, accepted resubmissions, priority reviews, and advisory committee preparation across gene therapy, vaccines, and rare disease assets.
Draft a post from this →Cancer development remains active but uneven, with positive readouts for Roche's giredestrant and J&J's multiple myeloma programs alongside the FDA lifting a hold on Merck and Daiichi Sankyo's ADC. Other signals show continued investor focus on oncology catalysts and the competitive ADC landscape in breast and lung cancer.
Draft a post from this →Large and mid-cap life sciences companies are using acquisitions and licensing to refill pipelines, buy capability, or diversify beyond core franchises. The set includes Lilly's acquisition of 4E Therapeutics, Pfizer's Veppanu deal completion, Roche's sizable Innovent pact, and broader M&A commentary about a 2026 takeover wave.
Draft a post from this →Several signals focus on the mechanics and cost of running trials, from phase definitions and dose selection to per-patient cost benchmarks and Bayesian methods. The cluster captures how sponsors are trying to make trials more efficient, scientifically rigorous, and cheaper as development budgets tighten.
Draft a post from this →Signals point to manufacturing as a central competitive lever, especially for cell and gene therapy and broader biopharma reshoring. Samsung Biologics, Lonza, and Danaher-related bioprocessing discussions emphasize capacity, flexibility, automation, decentralized production, and regulatory constraints on post-approval changes; J&J's Florida distribution hub also fits the supply-chain buildout theme.
Draft a post from this →